Latest On Oncternal Therapeutics, Inc (ONCT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-05 04:00 EST | News | Oncternal Therapeutics GAAP EPS of -$0.20 in-line, revenue of $0.2M beats by $0.06M | N/A |  |
| 2023-05-05 03:59 EST | News | Oncternal Therapeutics, Inc. (ONCT) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-04 02:39 EST | News | Oncternal Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-04-04 01:14 EST | News | Oncternal Therapeutics ends two cancer studies, stock craters ~31% after hours | N/A | |
| 2023-03-10 11:44 EST | News | Oncternal Therapeutics, Inc. (ONCT) Q4 2022 Earnings Call Transcript | N/A | |
About Oncternal Therapeutics, Inc (ONCT):
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. It also develops TK-216, a small-molecule that is designed to inhibit E26 transformation specific family of oncoproteins, which is in Phase I clinica read more...l trial to treat patients with Ewing sarcoma and in combination with vincristine chemotherapy. In addition, the company develops a chimeric antigen receptor-T product candidate that targets ROR1, which is in preclinical development for treating hematologic cancers and solid tumors. Oncternal Therapeutics, Inc. has a research and development collaboration with Karolinska Institutet to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK cells. The company is headquartered in San Diego, California.
General
- Name Oncternal Therapeutics, Inc
- Symbol ONCT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 12
- Last Split Factor1:7
- Last Split Date2019-06-10
- Fiscal Year EndDecember
- IPO Date2004-02-03
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.oncternal.com
Valuation
- Trailing PE 2.11
- Price/Sales (Trailing 12 Mt.) 42.39
- Price/Book (Most Recent Quarter) 19.79
- Enterprise Value Revenue 114.85
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.50
- Next Year EPS Estimate -$1.05
- Next Quarter EPS Estimate -$0.12
- Operating Margin -520%
- Return on Assets -16%
- Return on Equity -27%
- Revenue 3.38 million
- Earnings Per Share -$1.81
- Revenue Per Share $0.17
- Gross Profit -9169000
- Quarterly Earnings Growth 115.8%
Highlights
- Market Capitalization 436.24 million
- PE Ratio -0.34
- Analyst Target Price $15
- Book Value Per Share $1.18
Share Statistics
- Shares Outstanding 49.28 million
- Shares Float 43.48 million
- % Held by Insiders 2153%
- % Held by Institutions 17.22%
- Shares Short 89271
- Shares Short Prior Month 104119
- Short Ratio 0.06
Technicals
- 52 Week High $9.45
- 52 Week Low $1.49
- 50 Day Moving Average 6.79
- 200 Day Moving Average 4.15
Dividends
- Dividend Date 2019-06-10
- ExDividend Date N/A
- Dividend Yield 0%
Oncternal Therapeutics, Inc (ONCT) Dividend Calendar:
ONCT's last dividend payment was made to shareholders on June 10, 2019.
Oncternal Therapeutics, Inc (ONCT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Oncternal Therapeutics, Inc (ONCT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Oncternal Therapeutics, Inc (ONCT) Chart:
Oncternal Therapeutics, Inc (ONCT) News:
Below you will find a list of latest news for Oncternal Therapeutics, Inc (ONCT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Oncternal Therapeutics, Inc (ONCT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ONCT Trades:
Oncternal Therapeutics, Inc (ONCT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-04 | 8-K (Current report) | |
| 2020-11-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-09-09 | D (Notice of Exempt Offering of Securities) | |
| 2020-09-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-31 | 8-K (Current report) | |
| 2020-08-28 | FWP (Filing under Securities Act Rules 163/433 of free writing prospectuses) | |
| 2020-08-28 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-27 | 8-K (Current report) | |
| 2020-08-27 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-27 | FWP (Filing under Securities Act Rules 163/433 of free writing prospectuses) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-03 | D (Notice of Exempt Offering of Securities) | |
| 2020-07-31 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-07-31 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-07-31 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-07-31 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-07-31 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-07-31 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-07-31 | 4/A (Statement of changes in beneficial ownership of securities) | |
Oncternal Therapeutics, Inc (ONCT) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Oncternal Therapeutics, Inc (ONCT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2153%
Institutional Ownership: 1722%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-01 | MICHAEL G CARTER | Director | Buy | 71,429.00 | 2.10 | 150,000.90 | 71,947.00 | |
| 2020-07-21 | DANIEL L KISNER | Director | Buy | 10,000.00 | 2.38 | 23,825.00 | 10,000.00 | |
| 2020-07-21 | Shanghai Pharmaceutical (USA) Inc. | 10% Share Holder | Buy | 1,049,317.00 | 2.38 | 2,499,997.75 | 3,544,431.00 | |
| 2020-07-21 | HAZEL M AKER | Legal Counsel | Buy | 41,972.00 | 2.38 | 99,998.29 | 46,987.00 | |
| 2020-05-21 | DAVID F HALE | Director | Buy | 17,412.00 | 716,818.00 | |